Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NRP 2945

Next Previous
X
Search
Drug Profile

NRP 2945

Alternative Names: NNZ 4945; NRP 2945

Latest Information Update: 28 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Calzada; Neuren Pharmaceuticals
  • Developer CuroNZ
  • Class Antiepileptic drugs; Neuropeptides
  • Mechanism of Action CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Absence epilepsy
  • No development reported Amyotrophic lateral sclerosis; Angelman syndrome; Lennox-Gastaut syndrome; Rett syndrome
  • Discontinued Multiple sclerosis

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for research development in Angelman-syndrome in New Zealand (SC)
  • 28 Apr 2024 No recent reports of development identified for research development in Rett syndrome in New Zealand (SC)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in New Zealand (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top